A Multi-center, Open-label, Comparison and a Parallel Group Study (3 Groups) Phase 3 Clinical Trial for a Comparative Evaluation With the Existing Treatments, in Order to Verify the Long-term Efficacy and Safety of the First Cell Treatment Using Hearticellgram-AMI(Autologous Human Bone Marrow Derived Mesenchymal Stem Cells) in AMI Patients, and to Observe the Efficacy of the Second Cell Treatment.

Trial Profile

A Multi-center, Open-label, Comparison and a Parallel Group Study (3 Groups) Phase 3 Clinical Trial for a Comparative Evaluation With the Existing Treatments, in Order to Verify the Long-term Efficacy and Safety of the First Cell Treatment Using Hearticellgram-AMI(Autologous Human Bone Marrow Derived Mesenchymal Stem Cells) in AMI Patients, and to Observe the Efficacy of the Second Cell Treatment.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2015

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms RELIEF
  • Sponsors Pharmicell
  • Most Recent Events

    • 01 Feb 2015 Planned primary completion date changed from 1 Nov 2014 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
    • 14 Nov 2013 Planned end date changed from 1 Jan 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top